Publications
- First-line treatment for non-squamous NSCLC without driver mutations2022 | Third Faculty of Medicine
- Erlotinib in the first line treatment of the metastatic non-small cell lung cancer2018 | Third Faculty of Medicine
- Pleural mesothelioma2023 | Third Faculty of Medicine
- ALK-positive advanced non-small cell lung cancer patient with poor performance status - case report2023 | Third Faculty of Medicine
- Amivantamab in non‐small cell lung cancer treatment2023 | Third Faculty of Medicine
- Worse Prognosis in the Symptomatic Patients With Lung Cancer - Czech Multicentric Study2022 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Laboratory Parameters Associated with Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer2022 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer2022 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry2021 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
Loading network view...